Investor Presentaiton
Financial Results for FY2022
Revenue of Major Products in North America & China
FY2021
Resuts
FY2022
Results
Change
FY2021
Resuts
FY2022
Results
Value
Change
FX
impact
%
North America
Million $
Billions of yen
LATUDAⓇ
1,816
1,465
(351)
204.1
198.5
(5.6)
33.9
(2.8)
APTIOMⓇ
241
249
8
27.1
33.7
6.6
5.8
24.4
RETHYMICⓇ
3
33
30
0.3
4.4
4.1
0.8
BROVANAⓇ
129
21
(108)
14.5
2.8
(11.7)
KYNMOBIⓇ
5
3
(2)
0.6
0.4
(0.2)
0.5 (80.7)
0.1 (29.1)
ORGOVYXⓇ
83
182
99
9.3
24.7
15.4
4.2
164.9
MYFEMBREEⓇ
6
33
27
0.7
4.5
3.8
0.8
528.8
GEMTESAⓇ
63
182
119
7.1
24.7
17.5
4.2
246.0
Others
*
498
256
(242)
56.0
34.7
(21.2)
5.9
(38.0)
Total
2,845
2,424
(421)
319.8
328.5
8.7
56.0
2.7
China
MEROPENⓇ
Million RMB
Billions of yen
1,708
1,445
(263)
29.9
28.5
(1.4)
3.2
(4.6)
Others
Total
478
550
72
8.4
10.9
2.5
1.2
29.7
2,186
1,995
(191)
38.3
39.4
1.1
4.4
2.9
* Lump-sum revenue included in "Others"
FY2021
Revenue from the alliance with Otsuka of $270M
FY2022
Revenue from the license agreement for ORGOVYX® of $50M
Milestone revenue from approval of endometriosis of $38M
North America segment
Revenue increased due to the impact
of fluctuations in FX rates and products
of Sumitovant and its subsidiaries
■LATUDAⓇ revenue decreased due to a
decrease in shipment volume due to the
end of the exclusivity sales period in
February 2023 and a decrease in selling
prices due to changes in the payer mix
■BROVANAⓇ revenue decreased due to
loss of exclusivity in June 2021
Revenue from license
agreements included in "Others"
decreased (See the breakdown below
the table)
■ China segment
MEROPENⓇ revenue decreased due to
the impact of Volume-Based
Procurement application
FX rates:
FY2021 Results: 1US$ = ¥112.40, 1RMB = \17.52
FY2022 Results: 1US$ = ¥135.51, 1RMB = \19.75
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
5View entire presentation